153
Participants
Start Date
May 6, 2015
Primary Completion Date
July 29, 2020
Study Completion Date
July 31, 2020
ILUVIEN 0.19 MG
Macula Care, New York
Joseph R. Podhorzer, MD PLLC, Brooklyn
Ophthalmic Consultants of Long Island, Lynbrook
Pennsylvania Retina Specialist, PC, Camp Hill
Virginia Retina Center, Warrenton
University of Maryland Eye Associates, Baltimore
Johns Hopkins Hospital, Baltimore
Hampton Roads Retina Center, Chesapeake
Southeast Retina Center, P.C., Augusta
Southeastern Retina Associates, PC, Kingsport
Paducah Retinal Center, Paducah
Wayne State University, Detroit
Wolfe Eye Clinic, West Des Moines
Illinois Retina Associates, SC, Oak Park
Chicagoland Eye and Retina Foundation, Chicago
The University of Illinois at Chicago, Chicago
Carle Foundation Hospital, Urbana
University Retina and Macula Associates, Oak Forest
Lifelong Vision Foundation, Chesterfield
Discover Vision Centers, Independence
Sabates Eye Center Research Division, Leawood
Eye Associates of Northeast Louisiana, West Monroe
Tulsa Retina Consultants, Tulsa
Valley Retina Institute, PA, McAllen
Retina Research Center, Austin
Eye Care Center of Northern Colorado, Longmont
Retina Consultants of Arizona, Phoenix
Retina Centers, P.C., Tucson
Retina and Macula Institute, Glendale
Atlantis Eye Care, Huntington Beach
Orange County Retina Medical Group, Santa Ana
Retina Consultants of Hawaii, ‘Aiea
Cascade Eye and Skin, University Place
Northern California Retina Vitreous Medical Group, Inc., Mountain View
Retina Vitreous Associates of Florida, St. Petersburg
Island Retina, Shirley
Laurel Eye Clinic, Brookville
Medical Center Ophthalmology Associates, San Antonio
Eyesight Ophthalmic Services, PA, Portsmouth
New Jersey Retina, New Brunswick
Retina Associates of New Jersey, Teaneck
Lead Sponsor
Alimera Sciences
INDUSTRY